Advertisement

Topics

Lundbeck Pharma A/S Company Profile

23:34 EDT 18th September 2018 | BioPortfolio

Nil

Location

Dalbergstrøget 5
Taastrup
2630
Austria

Contact

Phone: 43 71 42 70
Fax: 43 71 42 74
Email: pharmainfo@lundbeck.com


News Articles [599 Associated News Articles listed on BioPortfolio]

Lundbeck Signs Near €1Bn Acquisition of Swiss Parkinson’s Biotech

Lundbeck is acquiring Prexton Therapeutics in a deal that could reach up to €905M if the Swiss company’s Parkinson’s treatment proves successful.  Danish pharma Lundbeck has decided to ...

Lundbeck to acquire Prexton Therapeutics adding foliglurax in clinical phase II to its pipeline of innovative treatments for patients suffering from Parkinson's disease

H. Lundbeck A/S (Lundbeck) and Prexton Therapeutics BV (Prexton) today announced signing of a definitive agreement in which Lundbeck will acquire Prexton. Under terms of the agreement, Lundbeck will p...

Lundbeck to buy Prexton Therapeutics in EUR905m deal

Danish pharma company H. Lundbeck has agreed to acquire Switzerland-based Prexton Therapeutics, which develops drugs for Parkinson's disease and other brain disorders, in a deal worth about DKK6.75bn ...

Lundbeck brings third Parkinson's drug into clinic

Denmark’s Lundbeck is bringing a third potential drug for Parkinson’s disease to the clinic – a human antibody that the company hopes will tackle the underlying cause of the condition. The comp...

#news #biotech After seeing POC data, Kyowa advances Parkinson’s program despite being dropped by Lundbeck 

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: After seeing POC data, Kyowa advances Parkinson’s program despite being dro...

H. Lundbeck A/S: Lundbeck to acquire Prexton Therapeutics adding foliglurax in clinical phase II to its pipeline of innovative treatments for patients suffering from Parkinson's disease

-- Lundbeck will make an upfront payment of EUR 100 million and the deal terms also include up to EUR 805 million in development, regulatory and sales milestones -- Foliglurax is a first-in-class t...

H. Lundbeck A/S: Lundbeck held its Annual General Meeting on 20 March 2018 at the company's registered office

Valby, Denmark, 2018-03-20 14:01 CET (GLOBE NEWSWIRE) -- Valby, Denmark, 20 March 2018 - H. Lundbeck A/S (Lundbeck) today announced that at the Annual General Meeting the report by the Board of Dir...

Lundbeck Reaches Across Atlantic, Picks Dunsire for CEO Post

Deborah Dunsire, a veteran of Boston’s biotech scene, is taking off. Specifically, she’s taking the top job at Danish pharma firm Lundbeck, according to an announcement this morning. The m...

Drugs and Medications [253 Associated Drugs and Medications listed on BioPortfolio]

Fluoride [Libertas Pharma, Inc.]

Fluoride Chewable Tablets 0.5 mg

Fluoride [Libertas Pharma, Inc.]

Fluoride Chewable Tablets 1 mg

Metoprolol tartrate [Med-Health Pharma, LLC]

Metoprolol Tartrate Tablets, USP

Urea [Libertas Pharma, Inc.]

Rx Only 45% Urea Nail Gel In a vehicle containing Camphor, Eucalyptus Oil and Menthol )

Eloxatin [Aventis Pharma Ltd.]

PubMed Articles [22 Associated PubMed Articles listed on BioPortfolio]

Data and Corporate Governance in Pharma and Digital Health: A Necessary Regulatory Convergence.

Data and Corporate Governance in Pharma and Digital Health: A Necessary Regulatory Convergence.

Clinical trials go virtual, big pharma dives in.

21 Century Citizen Pharma: The FDA & Patient-Focused Product Development.

Perpetual debate regarding the delicate balance between access and innovation and the protection of the public health and safety dominate discussions of the United States Food and Drug Administration ...

A guide to manufacturing CAR T cell therapies.

In recent years, chimeric antigen receptor (CAR) modified T cells have been used as a treatment for haematological malignancies in several phase I and II trials and with Kymriah of Novartis and Yescar...

Pharma APMs: Can the Industry Learn To Play Well With Others?

The alternative payment model (APM) is a nontraditional financial arrangement that rewards health care providers who deliver cost-effective, high-quality care. Now we are facing the possibility that p...

Clinical Trials [84 Associated Clinical Trials listed on BioPortfolio]

Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h)

The present clinical trial will be conducted in order to compare the bioavailability of rivastigmine and to assess bioequivalence at steady-state of the Test product RID-TDS 9.5 mg/24 h (L...

To Demonstrate the Relative Bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam Tablets In Healthy Adults Volunteers Under Fasting Conditions

To demonstrate the relative bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam tablets in healthy adult volunteers under fasting conditions.

Pharma-Pen (Formerly Innoject) Auto-Injectory TIV

The purpose of this study is to evaluate the safety, effectiveness, and tolerability, of the Pharma-Pen(TM) intramuscular (IM) and subcutaneous (SC) auto-injector systems used by untrained...

A Bioequivalence Study of Cefadroxil From Duricef 1 gm F.C.T (GSK) and Biodroxil 1 gm F.C.T (Novartis Pharma)

Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Cefadroxil from Duricef 1 gm Film Coated tablets(Smthkline Beecham Egypt,LLC aff...

Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition

The primary objective is to determine clinical bioequivalence of Amphotericin B liposome for injection of Auromedics Pharma LLC, USA and AmBisome (Amphotericin B) liposome for injection of...

Companies [776 Associated Companies listed on BioPortfolio]

Lundbeck LLC

Lundbeck in the U.S., headquartered in Deerfield, Illinois, is a wholly-owned subsidiary of H. Lundbeck A/S in Denmark. Lundbeck is committed to accelerating advances in brain dis...

LifeCycle Pharma

LifeCycle Pharma was founded in June 2002 as a spin-off from H. Lundbeck A/S. Its investors include H. Lundbeck A/S, Novo A/S, Nordic Biotech, Alta Partners (USA), and Adamant Biomedical Investments (...

Lundbeck Inc.

Lundbeck Inc. was established in March 2009 following the acquisition of Ovation Pharmaceuticals, Inc. by Lundbeck and has proven success in developing and commercializing high-ne...

Lundbeck Pharma A/S

Nil

Lundbeck

Depression, schizophrenia, Alzheimer's, Parkinson's, epilepsy, Multiple Sclerosis, and migraines have their foundation in the Central Nervous System - our key focus areas. Lundbeck's entire R&D effort...

More Information about "Lundbeck Pharma A/S" on BioPortfolio

We have published hundreds of Lundbeck Pharma A/S news stories on BioPortfolio along with dozens of Lundbeck Pharma A/S Clinical Trials and PubMed Articles about Lundbeck Pharma A/S for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Lundbeck Pharma A/S Companies in our database. You can also find out about relevant Lundbeck Pharma A/S Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record